Literature DB >> 20615343

Oral delivery systems for encapsulated bacteriophages targeted at Escherichia coli O157:H7 in feedlot cattle.

K Stanford1, T A McAllister, Y D Niu, T P Stephens, A Mazzocco, T E Waddell, R P Johnson.   

Abstract

Bacteriophages are natural predators of bacteria and may mitigate Escherichia coli O157:H7 in cattle and their environment. As bacteriophages targeted to E. coli O157:H7 (phages) lose activity at low pH, protection from gastric acidity may enhance efficacy of orally administered phages. Polymer encapsulation of four phages, wV8, rV5, wV7, and wV11, and exposure to pH 3.0 for 20 min resulted in an average 13.6% recovery of phages after release from encapsulation at pH 7.2. In contrast, untreated phages under similar conditions had a complete loss of activity. Steers (n = 24) received 10(11) CFU of naladixic acid-resistant E. coli O157:H7 on day 0 and were housed in six pens of four steers. Two pens were control (naladixic acid-resistant E. coli O157:H7 only), and the remaining pens received polymer-encapsulated phages (Ephage) on days -1, 1, 3, 6, and 8. Two pens received Ephage orally in gelatin capsules (bolus; 10(10) PFU per steer per day), and the remaining two pens received Ephage top-dressed on their feed (feed; estimated 10(11) PFU per steer per day). Shedding of E. coli O157:H7 was monitored for 10 weeks by collecting fecal grab and hide swab samples. Acceptable activity of mixed phages at delivery to steers was found for bolus and feed, averaging 1.82 and 1.13 x 10(9) PFU/g, respectively. However, Ephage did not reduce shedding of naladixic acid-resistant E. coli O157:H7, although duration of shedding was reduced by 14 days (P < 0.1) in bolus-fed steers as compared with control steers. Two successful systems for delivery of Ephage were developed, but a better understanding of phage-E. coli O157:H7 ecology is required to make phage therapy a viable strategy for mitigation of this organism in feedlot cattle.

Entities:  

Mesh:

Year:  2010        PMID: 20615343     DOI: 10.4315/0362-028x-73.7.1304

Source DB:  PubMed          Journal:  J Food Prot        ISSN: 0362-028X            Impact factor:   2.077


  24 in total

1.  Liposome-Encapsulated Bacteriophages for Enhanced Oral Phage Therapy against Salmonella spp.

Authors:  Joan Colom; Mary Cano-Sarabia; Jennifer Otero; Pilar Cortés; Daniel Maspoch; Montserrat Llagostera
Journal:  Appl Environ Microbiol       Date:  2015-05-08       Impact factor: 4.792

Review 2.  Phage Therapy in the Era of Synthetic Biology.

Authors:  E Magda Barbu; Kyle C Cady; Bolyn Hubby
Journal:  Cold Spring Harb Perspect Biol       Date:  2016-10-03       Impact factor: 10.005

Review 3.  Pharmacologically Aware Phage Therapy: Pharmacodynamic and Pharmacokinetic Obstacles to Phage Antibacterial Action in Animal and Human Bodies.

Authors:  Krystyna Dąbrowska; Stephen T Abedon
Journal:  Microbiol Mol Biol Rev       Date:  2019-10-30       Impact factor: 11.056

4.  Prophylactic Delivery of a Bacteriophage Cocktail in Feed Significantly Reduces Salmonella Colonization in Pigs.

Authors:  Anisha M Thanki; Guillaume Mignard; Robert J Atterbury; Paul Barrow; Andrew D Millard; Martha R J Clokie
Journal:  Microbiol Spectr       Date:  2022-05-17

5.  Genomic, proteomic and physiological characterization of a T5-like bacteriophage for control of Shiga toxin-producing Escherichia coli O157:H7.

Authors:  Yan D Niu; Kim Stanford; Andrew M Kropinski; Hans-Wolfgang Ackermann; Roger P Johnson; Yi-Min She; Rafiq Ahmed; Andre Villegas; Tim A McAllister
Journal:  PLoS One       Date:  2012-04-13       Impact factor: 3.240

Review 6.  Interventions for preventing diarrhea-associated hemolytic uremic syndrome: systematic review.

Authors:  Diana E Thomas; Elizabeth J Elliott
Journal:  BMC Public Health       Date:  2013-09-03       Impact factor: 3.295

Review 7.  Approaches to treatment of emerging Shiga toxin-producing Escherichia coli infections highlighting the O104:H4 serotype.

Authors:  Elias A Rahal; Sukayna M Fadlallah; Farah J Nassar; Natalie Kazzi; Ghassan M Matar
Journal:  Front Cell Infect Microbiol       Date:  2015-03-18       Impact factor: 5.293

Review 8.  Clinical Pharmacology of Bacteriophage Therapy: A Focus on Multidrug-Resistant Pseudomonas aeruginosa Infections.

Authors:  Dana Holger; Razieh Kebriaei; Taylor Morrisette; Katherine Lev; Jose Alexander; Michael Rybak
Journal:  Antibiotics (Basel)       Date:  2021-05-11

9.  The host-range, genomics and proteomics of Escherichia coli O157:H7 bacteriophage rV5.

Authors:  Andrew M Kropinski; Tom Waddell; Juncai Meng; Kristyn Franklin; Hans-Wolfgang Ackermann; Rafiq Ahmed; Amanda Mazzocco; John Yates; Erika J Lingohr; Roger P Johnson
Journal:  Virol J       Date:  2013-03-06       Impact factor: 4.099

10.  Bacteriophages and their role in food safety.

Authors:  Sanna M Sillankorva; Hugo Oliveira; Joana Azeredo
Journal:  Int J Microbiol       Date:  2012-12-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.